JAZZ Q3 2025 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena

JAZZJazz Pharmaceuticals plc

$12B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1.1B+6.7% YoY

Gross Profit

$868M77.1% margin

Operating Income

$58M5.1% margin

Net Income

$251M22.3% margin

EPS (Diluted)

$4.08

QoQ Revenue Growth

+7.7%

Cash Flow

Operating Cash Flow

$475M

Free Cash Flow

$459M

Stock-Based Comp.

$88M

Balance Sheet

Total Assets

$11.4B

Total Liabilities

$7.4B

Stockholders' Equity

$4.0B

Cash & Equivalents

$1.2B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.1B	$1.1B	+6.7%
Gross Profit	$868M	$943M	-8.0%
Operating Income	$58M	$260M	-77.9%
Net Income	$251M	$215M	+16.9%

Revenue Segments

Xywav

$431M39%

Epidiolex/Epidyolex

$303M27%

Rylaze/Enrylaze

$100M9%

Zepzelca

$79M7%

High Sodium AG Oxybate Product Royalty Revenue

$53M5%

Defitelio/Defibrotide

$52M5%

Vyxeos

$38M3%

Xyrem

$36M3%

Other Royalty And Contract Revenues

$9M1%

Ziihera

$8M1%

Sativex

$5M0%

Other Products

$2M0%

Geographic Segments

UNITED STATES

$1.0B91%

Europe

$86M8%

Other Countries

$19M2%